


From Isolation to Integration: A national model for liver cancer and cirrhosis support

Presented by: Megan Collins
Clinical Nurse Consultant



** I have no disclosures*



Acknowledgement of country

We acknowledge the Traditional Custodians of the lands where we work and the places in which we live. We pay respect to Ancestors and Elders past and present.

We recognise the unique cultural and spiritual relationship and celebrate the contributions of First Nations peoples to Australia.



Artwork by Elizabeth Close, an Anangu woman from the Pitjantjatjara and Yankunytjatjara Language Groups

Liver Cancer in Australia

2nd most common cause of cancer related mortality and 3rd most common cause of cancer related death in Australia



Liver cancer costs Australia \$4.8 Billion every year³



3,175

Estimated number of new cases of liver cancer diagnosed in 2025



1.9%

Estimated % of all new cancer cases diagnosed in 2025



24.6%

Chance of surviving at least 5 years (2017–2021)



4,974

People living with liver cancer at the end of 2021 (diagnosed in the 5-year period 2016 to 2020)



2,632

Estimated number of deaths from liver cancer in 2025



4.9%

Estimated % of all deaths from cancer in 2025



9-11%


Chance of surviving at least 5 years for Aboriginal and Torres Strait Islander People²

Global prevalence of MAFLD-related Hepatocellular carcinoma: A systematic review and meta-analysis

Aim: Estimate the global proportion of HCC attributable to MAFLD as:

- A sole liver disease
- In combination with other liver diseases

22 studies, **56,565** individuals with HCC included



GLOBAL HCC BURDEN



12% of HCC globally is due to **MAFLD as sole liver disease**


49% in total have **MAFLD** (with or without other liver diseases)

HBV-RELATED HCC



40% of **HBV** related HCC have MAFLD

HCV-RELATED HCC




54% of **HCV** related HCC have MAFLD

ALCOHOL-RELATED HCC



64% of **alcohol-related** HCC have MAFLD

Note. From Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis, by Crane et al., 2024, Clinical and Molecular Hepatology, 30(3), p. 436. Copyright 2024 by The Korean Association for the Study of the Liver



- Australia's first dedicated liver cancer support line
- Free, confidential, non-judgemental telehealth service staffed by nurses, dietitian and counsellor
- Support for:
 - People diagnosed with primary liver cancer or liver disease
 - Carers, family & friends
 - Healthcare professionals seeking guidance
- Open weekdays, 8:00 AM – 6:00 PM AEDT
- Interpreters available for 150+ languages & Auslan



- Call 1800 841 118
- Email support@liver.org.au
- Direct chat through website
- Request a call-back: liver.org.au/support-line
- We also accept referrals from health professionals who want us to contact their patients: <https://liver.org.au/health-professionals/support-line-for-your-patients/>

Liver Foundation Service Flow

How our core programs connect to support the community

Free Education

Broome
5th August

Port Lincoln
30th September



Frontline Liver Care
Empowering Healthcare
Workers

Cairns
26th October

Merimbula
4th November

Community of Practice




Liver Foundation Nursing Community of Practice
A space for nurses, by nurses

Patient Support & Information



Resources





Thank You

- Questions?
- Contact us:
 - support@liver.org.au
 - 1800 841 118
- Let's work together to support Australians affected by liver cancer and underlying liver disease

